Top Markets
Coin of the day
OptiNose, Inc. OptiNose, Inc.

OptiNose, Inc.

OPTN
Κατάταξη σε μετοχές #9145
OptiNose, Inc. is a specialized pharmaceutical company primarily focused on... OptiNose, Inc. is a specialized pharmaceutical company primarily focused on innovating and bringing to market treatments for individuals under the care of ear, nose, throat, and allergy specialists throughout the United States. Its flagship product, XHANCE, utilizes the company's proprietary exhalation delivery system (EDS) to administer a topically-acting corticosteroid. This therapy is approved for treating chronic rhinosinusitis when accompanied by nasal polyps and is currently undergoing Phase IIIb clinical trials for broader chronic sinusitis treatment. The company also offers Onzetra Xsail, a powder-based EDS device, which is commercialized via a licensing agreement with Currax Pharmaceuticals LLC. Further expanding its pipeline, OptiNose is developing OPN-019, an investigational product that integrates a liquid EDS device with an antiseptic agent. Additionally, OptiNose has formed a partnership with Inexia Limited. This collaboration centers on the development, manufacturing, importation, and sale of products containing orexin receptor agonist or positive modulator molecules, intended for the treatment, diagnosis, or prevention of human conditions predominantly linked to orexin receptor activity. Established in 2000, OptiNose, Inc. operates from its corporate headquarters in Yardley, Pennsylvania.
Τιμή μετοχής
$9.60
Τελευταίος συγχρονισμός: 2025-05-21
Κεφαλαιοποίηση
$1.08B
Αλλαγή (1 ημέρα)
0.00%
Αλλαγή (1 έτος)
0.00%
Χώρα
US
Εμπόριο OptiNose, Inc. (OPTN)

Κατηγορία

Κέρδη για την OptiNose, Inc. (OPTN)
Κέρδη τον Mar 2025 TTM: $-29.89M
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της OptiNose, Inc., τα τρέχοντα κέρδη της εταιρείας είναι $-29.89M. Το 2023, η εταιρεία παρουσίασε κέρδη $-35.48M, αύξηση σε σχέση με των κερδών του 2022 που ήταν $-74.83M. Τα κέρδη που εμφανίζονται σε αυτή τη σελίδα είναι πριν από τόκους και φόρους, γνωστά και ως EBIT.
Ιστορικό κερδών για την OptiNose, Inc. από 2015 έως 2026
Κέρδη στο τέλος κάθε έτους
Έτος Κέρδη Αλλαγή
2026 (TTM) $-29.89M 38.76%
2024 $-21.54M -39.29%
2023 $-35.48M -52.58%
2022 $-74.83M -9.07%
2021 $-82.30M -17.53%
2020 $-99.79M -9.33%
2019 $-110.05M 3.18%
2018 $-106.66M 118.11%
2017 $-48.90M -316.26%
2016 $22.61M -179.87%
2015 $-28.31M 0.00%
Κέρδη παρόμοιων εταιρειών ή ανταγωνιστών